Valuation: Atrion Corporation

Market Cap 81Cr 71Cr 65Cr 60Cr 114.45Cr 7.72TCr 116.37Cr 780.29Cr 306.42Cr 3.8TCr 303.92Cr 297.31Cr 13TCr P/E 2022
28.6x
P/E 2023 34.4x
Enterprise Value 80Cr 70Cr 65Cr 60Cr 113.6Cr 7.66TCr 115.51Cr 774.49Cr 304.14Cr 3.77TCr 301.66Cr 295.1Cr 13TCr EV / Sales 2022
5.27x
EV / Sales 2023 3.9x
Free-Float
50.88%
Yield 2022
1.47%
Yield 2023 2.3%
3 years 274.98
Extreme 274.98
593
5 years 274.98
Extreme 274.98
805.62
10 years 274.98
Extreme 274.98
948.03
Manager TitleAgeSince
Corporate Secretary 53 21/08/2024
Director TitleAgeSince
Director/Board Member 53 21/08/2024
Date Insider Type Main position Quantity % Market Cap.
21/24/21Issuer sale

Chief Executive Officer

98,614 5.6032%
21/24/21Issuer sale

Director

499 0.0284%
21/24/21Issuer sale

Chief Financial Officer

2,223 0.1263%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-.--%-.--%-14.25% 81Cr
-0.50%-1.54%-29.69%-12.23% 16TCr
+1.80%+0.82%-6.19%-2.98% 11TCr
+0.32%+2.34%+2.06%+57.36% 5.9TCr
+0.79%-3.68%+40.47%+55.85% 5.17TCr
+0.72%-3.88%-14.40%-41.01% 4.19TCr
+0.47%-4.98% - - 3.47TCr
+2.66%+5.21%-12.29%-42.61% 2.89TCr
-1.10%-3.29%+54.30%-6.25% 2.5TCr
0.00%-1.01%-6.38%-3.16% 2.11TCr
Average +0.79%-0.93%+3.10%-1.03% 5.34TCr
Weighted average by Cap. +1.32%-0.93%-6.09%+1.54%

Financials

2022 2023
Net sales 18Cr 16Cr 15Cr 14Cr 26Cr 1.75TCr 26Cr 176.9Cr 69Cr 862.19Cr 69Cr 67Cr 2.96TCr 17Cr 15Cr 14Cr 13Cr 24Cr 1.61TCr 24Cr 163.23Cr 64Cr 795.57Cr 64Cr 62Cr 2.73TCr
Net income 3.5Cr 3.06Cr 2.82Cr 2.61Cr 4.95Cr 333.89Cr 5.03Cr 34Cr 13Cr 164.48Cr 13Cr 13Cr 565.46Cr 1.94Cr 1.7Cr 1.57Cr 1.45Cr 2.74Cr 185.13Cr 2.79Cr 19Cr 7.35Cr 91Cr 7.29Cr 7.13Cr 313.53Cr
Net Debt -2.52Cr -2.21Cr -2.03Cr -1.88Cr -3.56Cr -240.45Cr -3.62Cr -24Cr -9.54Cr -118.45Cr -9.47Cr -9.26Cr -407.21Cr -60.16L -52.62L -48.54L -44.83L -85.06L -57Cr -86.49L -5.8Cr -2.28Cr -28Cr -2.26Cr -2.21Cr -97Cr
Logo Atrion Corporation
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.
Employees
712
  1. Stock Market
  2. Stocks
  3. ATRI Stock